Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy.

Jessica P HwangMaria E Suarez-AlmazorScott B CantorAndrea BarboHeather Y LinSairah AhmedMariana Chavez-MacGregorChristian Donato-SantanaCathy EngAlessandra FerrajoliMichael J FischPeter McLaughlinGeorge R SimonGabriela RondonElizabeth J ShpallAnna S Lok

Published in: Cancer (2017)

Early identification correlates with early anti-HBV therapy and reduces the risk of liver failure and death in chronic HBV patients receiving chemotherapy. Cancer 2017;123:3367-76. © 2017 American Cancer Society.

Keyphrases

hepatitis b virus
liver failure
papillary thyroid
cancer therapy
squamous cell
drug delivery
lymph node metastasis
type diabetes
radiation therapy
stem cells
squamous cell carcinoma
locally advanced
young adults
mesenchymal stem cells
skeletal muscle
electronic health record